Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow HYPD by emailGet an email when HYPD pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about HYPD, unsubscribe in one click. Privacy
📣 What HYPD Says Is Next
in 2026 · “For the past two quarters, 40%-50% of our Adjusted Gross Profit (1) was denominated in cash, cash equivalents, and stablecoins (16) . · Guidance: We continue to anticipate $5 million to $7 million Adjusted Gross Profit (1) in 2026, approximately 5x our 2025 FY results.”
Company press release, Aug 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full HYPD picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for HYPD and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.